Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
37.59
+0.28 (0.75%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 95.93, with a low estimate of 48 and a high estimate of 140. The average target predicts an increase of 155.20% from the current stock price of 37.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $104 → $117 | Buy | Maintains | $104 → $117 | +211.25% | Mar 27, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $140 → $115 | Buy | Maintains | $140 → $115 | +205.93% | Mar 17, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $118 | Buy | Reiterates | $118 | +213.91% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +152.73% | Feb 18, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $121 → $136 | Strong Buy | Maintains | $121 → $136 | +261.80% | Feb 18, 2025 |
Financial Forecast
Revenue This Year
668.35M
from 560.23M
Increased by 19.30%
Revenue Next Year
863.55M
from 668.35M
Increased by 29.21%
EPS This Year
-5.05
from -6.29
EPS Next Year
-3.57
from -5.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 701.6M | 1.1B | 1.7B | ||
| Avg | 668.4M | 863.6M | 1.3B | ||
| Low | 623.9M | 690.0M | 794.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.2% | 59.5% | 100.7% | ||
| Avg | 19.3% | 29.2% | 48.1% | ||
| Low | 11.4% | 3.2% | -8.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.85 | -0.23 | 5.89 | ||
| Avg | -5.05 | -3.57 | -0.27 | ||
| Low | -6.02 | -5.42 | -3.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.